BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/2/2025 10:54:13 AM | Browse: 268 | Download: 1131
 |
Received |
|
2024-08-30 06:01 |
|
Peer-Review Started |
|
2024-09-05 04:55 |
|
First Decision by Editorial Office Director |
|
2025-01-22 05:56 |
|
Return for Revision |
|
2025-01-22 05:56 |
|
Revised |
|
2025-02-22 14:29 |
|
Publication Fee Transferred |
|
2025-02-24 08:43 |
|
Second Decision by Editor |
|
2025-03-18 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-03-18 05:55 |
|
Articles in Press |
|
2025-03-18 05:55 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-24 07:21 |
|
Publish the Manuscript Online |
|
2025-04-02 10:54 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better?
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xue-Er Yang, Sheng-Jun Zhang, Yuan Liu, Shuo-Yi Yao, Su-Xin Zhang, Xiao-Ming Liu, Lun-Xi Liang and Fen Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82270594 |
| National Natural Science Foundation for Youths of China |
82103151 |
| Outstanding Youth Foundation of Hunan Province |
2022JJ20092 |
| Wisdom Accumulation and Talent Cultivation Project of Third Xiangya Hospital of Central South University |
YX202103 |
|
| Corresponding Author |
Fen Wang, MD, PhD, Professor, Department of Gastroenterology, the Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Changsha 410013, Hunan Province, China. wfen-judy@csu.edu.cn |
| Key Words |
Helicobacter pylori; High-dose dual therapy; Esomeprazole; Vonoprazan; Eradication rate |
| Core Tip |
The global burden of Helicobacter pylori infection is high. Triple and quadruple therapies are both classical regimens. The effect of high-dose dual therapy (HDDT) compared to classical regimens in different regions/populations is unclear. Our study found HDDT based on vonoprazan was non-inferior to the vonoprazan triple regimen. Classical quadruple therapy had a higher eradication rate than HDDT based on esomeprazole, but in modified intention-to-treat and per-protocol analysis, EA therapy was non-inferior to B-quadruple therapy. |
| Publish Date |
2025-04-02 10:54 |
| Citation |
Yang XE, Zhang SJ, Liu Y, Yao SY, Zhang SX, Liu XM, Liang LX, Wang F. Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better? World J Gastroenterol 2025; 31(13): 100863 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i13/100863.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i13.100863 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
